Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04333823 · ClinicalTrials.gov registry record · Phase 3
Adolescent Type 1 Diabetes Treatment With SGLT2i for hyperglycEMia & hyPerfilTration Trial
A Phase 3 study, sponsored by The Hospital for Sick Children.
- Active
- Registry status
- Phase 3
- Development phase
- 100
- Enrollment target
NCT04333823 is a Phase 3 study that is active but no longer recruiting, run by The Hospital for Sick Children. The registered enrollment target is 100 participants.
The verdict
NCT04333823, a Phase 3 study, is active but no longer recruiting, sponsored by The Hospital for Sick Children.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 100 participants
- Enrollment target
Study Summary
The ATTEMPT (Adolescent Type 1 diabetes Treatment with SGLT2i for hyperglycEMia \& hyPerfilTration Trial) is a multi-center, double-blinded, randomized, placebo-controlled trial to evaluate the effect of treatment with Dapagliflozin when compared to placebo, in combination with adjustable insulin, on measured GFR in adolescents with T1D 12 to \<19 years of age over a 16-week treatment period.
Interventions
- DRUG Placebo
- DRUG Dapagliflozin 5mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2020-12-11 |
| Est. Completion | 2024-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04333823
The ClinicalTrials.gov registry entry for NCT04333823 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The Hospital for Sick Children, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04333823 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04333823 about?
NCT04333823 is a clinical study titled "Adolescent Type 1 Diabetes Treatment With SGLT2i for hyperglycEMia & hyPerfilTration Trial". The ATTEMPT (Adolescent Type 1 diabetes Treatment with SGLT2i for hyperglycEMia \& hyPerfilTration Trial) is a multi-center, double-blinded, randomized, placebo-controlled trial to evaluate the effect of treatment with Dapagliflozin when compared to placebo, in combination with adjustable insulin, o...
What is the current status of trial NCT04333823?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 100 participants. The study started on 2020-12-11. Estimated completion is 2024-05.
What interventions are being tested in trial NCT04333823?
The interventions under investigation include: Placebo (DRUG), Dapagliflozin 5mg (DRUG).
Who is sponsoring clinical trial NCT04333823?
This trial is sponsored by The Hospital for Sick Children, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.